Spironolactone Use in Patients with Chronic Kidney Disease

Introduction to Spironolactone Therapy

• The European Society of Cardiology recommends that spironolactone should be avoided in patients with severe CKD (eGFR <30 mL/min/1.73m²) and serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women due to prohibitively high risk of life-threatening hyperkalemia 1, 2.

Absolute Contraindications

• The American Heart Association notes that serum potassium ≥5.0 mEq/L at baseline is an absolute contraindication for spironolactone therapy 1, 2, 3.
• The European Heart Journal guidelines state that eGFR <30 mL/min/1.73m² or serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) are absolute contraindications for spironolactone use 1, 2, 3.

Initiation Protocol for Moderate CKD

• For patients with eGFR 30-50 mL/min/1.73m², the European Society of Cardiology recommends starting with 12.5 mg daily or 25 mg every other day—NOT the standard 25 mg daily dose 2, 4.

Pre-initiation Requirements

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend verifying serum potassium <5.0 mEq/L before initiating spironolactone therapy 1, 3, 4.
• The American Diabetes Association (ADA) suggests confirming eGFR >30 mL/min/1.73m² (use eGFR, not serum creatinine alone, especially in elderly patients where creatinine underestimates dysfunction) before starting spironolactone 4.

Monitoring Schedule

• The European Society of Cardiology recommends checking potassium and renal function at 3 days and 1 week after initiation, and then at least monthly for the first 3 months 4, 3.

Management of Hyperkalemia During Treatment

• If potassium 5.5-5.9 mEq/L, the European Heart Journal guidelines recommend reducing the dose to 25 mg every other day or 12.5 mg daily and rechecking within 1 week 3, 4.
• If potassium ≥6.0 mEq/L, the American Heart Association recommends discontinuing spironolactone immediately and implementing specific hyperkalemia treatment 1, 3, 5.

Critical Risk Factors for Hyperkalemia

• The European Society of Cardiology notes that concomitant ACE inhibitor or ARB use (especially at higher doses) exponentially increases hyperkalemia risk and warrants extreme caution or avoidance 4.
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that diabetes mellitus is a critical risk factor for hyperkalemia in patients taking spironolactone 6.

Special Populations

Heart Failure with CKD

• The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) consensus notes that spironolactone reduces mortality in heart failure with reduced ejection fraction, but causes hyperkalemia particularly with eGFR <45 mL/min/1.73m² 7, 6.

Elderly Patients

• The European Heart Journal guidelines classify spironolactone and eplerenone as potentially inappropriate medications in elderly patients with serum creatinine >2.5 mg/dL or potassium >5.0 mmol/L (spironolactone) or >5.5 mmol/L (eplerenone) 1.

Common Pitfalls to Avoid

• The European Society of Cardiology recommends using eGFR instead of serum creatinine for renal assessment, particularly in elderly or sarcopenic patients 4.
• The American Heart Association suggests avoiding continuing potassium supplements after spironolactone initiation 4.

Alternative Approaches for Severe CKD

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering hydralazine-isosorbide dinitrate combination or other antihypertensive classes with better safety profiles in advanced kidney disease for patients with eGFR <30 mL/min/1.73m² requiring additional blood pressure control or heart failure management 8.

Spironolactone Contraindication in CKD Stage 4

Guideline Recommendations

• Spironolactone must be discontinued immediately in patients with CKD stage 4 (eGFR 15‑29 mL/min/1.73 m²) because of a prohibitively high risk of life‑threatening hyperkalemia. – American College of Cardiology (ACC) 2022 HF Guidelines 9
• An eGFR < 30 mL/min/1.73 m² is an absolute contraindication to spironolactone therapy as stipulated by the 2022 ACC/AHA Heart Failure Guidelines and the European Society of Cardiology (ESC) guidelines. – ACC & ESC 9
• The ACC/AHA recommends mineralocorticoid receptor antagonists (MRAs) only when eGFR > 30 mL/min/1.73 m² and serum potassium < 5.0 mEq/L. – ACC 2022 HF Guidelines 9

Risk Factors and Clinical Indicators

• Metolazone “burst” therapy signals diuretic resistance, indicating advanced heart failure and further compromised renal function. – European Heart Journal 2001; Circulation 2013 10, 11

Alternative Management Strategies

• Maintain maximized loop diuretic (bumetanide) with intermittent metolazone bursts for sequential nephron blockade in lieu of MRAs. – European Heart Journal 2001; Circulation 2013 10, 11
• Thiazide‑type diuretics may be used for blood‑pressure control, but their efficacy markedly declines when eGFR < 30 mL/min/1.73 m². – Circulation 2013 11
• Potassium‑sparing diuretics should be avoided entirely at this level of renal function. – European Heart Journal 2001; Circulation 2013 10, 11
• If tolerated and serum potassium permits, ACE‑inhibitor or ARB dosing should be optimized. – ACC 2022 HF Guidelines; additional ACC 2022 evidence 9, 12
• Beta‑blocker therapy should be maximized according to guideline‑directed heart‑failure care. – ACC 2022 HF Guidelines; additional ACC 2022 evidence 9, 12
• SGLT2 inhibitors can be considered when eGFR ≥ 20 mL/min/1.73 m² and the patient has diabetes. – Kidney International 2022 13

Implementation Steps

• Discontinue spironolactone today. – ACC 2022 HF Guidelines 9
• Document the absolute contraindication in the medical record to prevent inadvertent re‑initiation. – ACC 2022 HF Guidelines 9
• Reassess volume status and adjust loop‑diuretic dosing after spironolactone withdrawal. – Circulation 2013 11

Spironolactone Use in Chronic Kidney Disease – Evidence‑Based Recommendations

1. Absolute Contra‑indications

• Serum creatinine > 2.5 mg/dL in men or > 2.0 mg/dL in women precludes spironolactone use because of prohibitive hyper‑kalemia risk. European Society of Cardiology guideline (based on European Heart Journal 2008) 14
• Concurrent use of an ACE‑inhibitor and an ARB is an absolute contraindication due to synergistic potassium‑retaining effects. Hypertension guideline (Hypertension 2008) 15

2. Dosing Recommendations for Moderate CKD

• Standard 25 mg daily dose is appropriate only when eGFR > 60 mL/min/1.73 m²; lower renal function requires dose reduction. European Society of Cardiology guideline (European Heart Journal 2008) 14

3. Management of Hyper‑kalemia During Therapy

• If serum potassium rises to 5.5–5.9 mmol/L: reduce spironolactone to 12.5 mg daily or 25 mg every other day, repeat labs within 1 week, and review for NSAIDs, potassium‑rich foods, or intercurrent illness. European Society of Cardiology guideline (European Heart Journal 2008) 14
• If serum potassium reaches ≥ 6.0 mmol/L: stop spironolactone immediately, initiate acute hyper‑kalemia treatment per protocol, monitor chemistry closely, and document the contraindication to avoid re‑initiation. European Society of Cardiology guideline (European Heart Journal 2008) 14

4. Patient‑specific Risk Factors that Amplify Hyper‑kalemia

5. Cardiovascular Outcomes in Heart Failure with Mild‑Moderate CKD

• Spironolactone reduces mortality in HFrEF even when eGFR is 30–59 mL/min/1.73 m², provided the contraindications and monitoring protocol are followed. European Society of Cardiology guideline (European Heart Journal 2008) 14
• RALES trial (RCT, high‑quality evidence) showed a 30 % relative risk reduction in death for NYHA class III–IV heart‑failure patients receiving spironolactone; only 11 % were on beta‑blockers at the time. European Society of Cardiology guideline (European Heart Journal 2008) 14

6. Adverse‑effect Profile

• Gynecomastia occurs in ≈ 9 % of male patients receiving an average dose of 26 mg daily; onset ranges from 1–2 months to > 1 year. European Society of Cardiology guideline (European Heart Journal 2008) 14
• If gynecomastia develops, switching to eplerenone 25–50 mg daily is advised because it carries a lower risk of sexual‑related side effects. European Society of Cardiology guideline (European Heart Journal 2008) 14